← All indications
Carcinoma in Situ
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Subtype terms (3)
More specific conditions that are subtypes of Carcinoma in Situ in the MeSH hierarchy.
- Adenocarcinoma in Situ
2 drugs approved
- Breast Carcinoma In Situ
12 drugs (11 approved, 1 experimental)
- Prostatic Intraepithelial Neoplasia
7 drugs (3 approved, 4 experimental)
Drugs by status
Phase 3 trials (8)
Phase 2 trials (4)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (57)
- Endo Pharmaceuticals
- GTx
- Medical Enterprises Europe B.V.
- Photocure
- Cold Genesys, Inc.
- National Cancer Institute (NCI)
- United States Navy
- Ente Ospedaliero Ospedali Galliera
- Academic and Community Cancer Research United
- Maastricht University
- Medical University of Graz
- Albert Schweitzer Hospital
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- University of London
- Cornell University
- Harvard University
- International Breast Cancer Study Group
- Kaohsiung Medical University
- Kyoto University
- McMaster University
- Meander Medical Center
- Medical University Innsbruck
- NRG Oncology
- North Central Cancer Treatment Group
- Radiation Therapy Oncology Group
- Sint Franciscus Gasthuis
- Southwest Oncology Group
- University of Milan
- +27 more
Organization Involved with Phase 2 Indications (81)
- Peplin
- Incyte
- DFB Pharma
- Roche
- Advaxis, Inc.
- AstraZeneca
- Merck
- Pfizer
- Novartis
- Atossa Genetics, Inc.
- BioLeaders Corporation
- Cutanea Life Sciences, Inc.
- Erimos Pharmaceuticals
- Inovio Pharmaceuticals
- ISA Pharmaceuticals
- Shanghai Zhangjiang Biotechnology Limited Company
- Sirnaomics
- Theradex
- Telormedix SA
- Vaccibody AS
- Windy Hill Medical, Inc.
- Genexine, Inc.
- The EMMES Corporation
- Planned Parenthood
- United States Army
- Aarhus University
- University of Arizona
- University of Pittsburgh
- AIDS Malignancy Consortium
- Baylor University
- +51 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (15)
- DUSA Pharmaceuticals
- GlaxoSmithKline
- National Institutes of Health (NIH)
- Dr. Susan Love Research Foundation
- Cedars-Sinai Medical Center
- Indiana University
- Rhode Island Hospital
- Virginia Commonwealth University
- Wake Forest University
- Yale University
- Quadram Institute
- University of Chicago
- Institute of Food Research, Norwich
- Clinical Trial Center Maastricht
- California Breast Cancer Research Program